New Strategies for Gene Therapy - A Bioscience Centre Conference
	the Bioscience Centre, the International Centre for Life , Newcastle upon Tyne 28th September 1999
	28th September 1999, 6.00 pm - 7.15 pm welcome reception 29th September 1999, 9.30 am - 5.30 pm conference sessions 8.00 pm conference dinner 30th September 1999, 9.30 am - 3.00 pm conference sessions All timings subject to confirmation.
	Organized by:	The Bioscience centre with Benchmark Communications
	Invited Speakers:	New Approaches in Cancer Gene Therapy. Describing the integration of various recent cancer therapy strategies into a co-ordinated therapeutic approach. Dr Georges Vassaux, ICRF, Hammersmith Hospital Development of a mutli-CTL epitope DNA prime-MVA boost vaccine for HIV. Induction of CTL and their role(s) in the control of HIV infection. Dr Tomas Hanke, MRC Human Immunology Unit, The John Radcliffe Hospital, Oxford University Additional Speakers: Novel Technologies for the Treatment of Cytokine and Cytokine-receptor Related Diseases. Novel technologies of pre-transcriptional regulation using promoter inhibitors, and post-transcriptional regulation using ribozymes, have been developed to inhibit cytokines and cytokine receptors involved in pathogenesis of diseases. Dr Richard Zheng, Queen Mary and Westfield College Gene Therapy – Unrequited Promise or Millennial Blockbuster? Gene Therapy has now been around for 10 years. This talk will discuss progress in gene therapy and the current prospects for gene therapy products. Dr David Thatcher, Cobra Therapeutics Development of the Adenovirus as a Gene Transfer Vector. Its use in gene therapy and gene therapeutics and its application in skeletal muscle as a model example. Dr Michael Roberts, Royal Holloway and Bedford New College Oligonucleotide Strategies for Gene Correction: Chimaeroplasts and Splicomers. The use of oligonucleotides as an alternative to conventional gene therapy approaches with an emphasis on the treatment of neuromuscular disease. Dr Ian Graham, Royal Holloway and Bedford New College Gene Therapy for Ischaemic Disease. Transcriptional targeting and cell based gene therapy utilising a range of vector systems for the treatment of ischaemic diseases including solid tumours, arthritis, peripheral arterial disease and cardiovascular disease. Dr Stuart Naylor, Oxford Biomedica Mitochondrial Gene Therapy. Defects of mitochondrial DNA are an important cause of disease currently with no effective treatment. Correcting mitochondrial gene defects presents many different challenges to nuclear gene therapy. Professor Douglas Turnbull, Department of Neurology, University of Newcastle Progress Towards Third Generation Non-Viral Vectors for Gene Therapy. Liposomal gene therapy delivery. Dr Andrew Miller, Department of Organic Chemistry, Imperial College Gene Therapy of Cystic Fibrosis using a liposome delivery system. Dr Eric Alton, Imperial College Adenovirus-mediated gene transfer. Professor George Dickson, Royal Holloway and Bedford New College And more to be confirmed.
	Deadline for Abstracts:	N/A
	Registration:	Conference fees: Full 2-day conference rate: £799.00 (+ £140.00 VAT) = £939.00 Full 1-day conference rate: £425.00 (+£74.38 VAT) = £499.38 Academic 2-day conference rate: £599.00 (+ £104.83 VAT) = £703.83 Academic 1-day conference rate: £325.00 (+ £56.88 VAT) = £381.88 These rates all include the conference dinner on the evening of 29th September. For further information and to book contact the conference organisers: Sue Reay or Claire Molloy Benchmark Communications Design Works William Street Felling Gateshead UK NE10 0JP Tel: +44 191 421 0082 Fax: +44 191 438 1867
	Email for Requests and Registration:	bioscience.conferences@benchcom.co.uk
	Posted by: Claire Molloy   Host: dw-rtr-01.north-east.co.uk date: July 28, 1999 21:10:37 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.